CRISPR

CRISPR3-slc6a3

ID

ZDB-CRISPR-200115-1

Name

CRISPR3-slc6a3

Previous Names

None

Target

slc6a3 (1)

Sequence

5' - GGAGTACTAATTGAGGCCATCGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
zf3173	slc6a3

Expression

Gene expression in Wild Types + CRISPR3-slc6a3

No data available

Phenotype

Phenotype resulting from CRISPR3-slc6a3

No data available

Phenotype of all Fish created by or utilizing CRISPR3-slc6a3

Phenotype	Fish	Conditions	Figures
swimming behavior process quality, abnormal	slc6a3^{zf3173/zf3173}	standard conditions	Fig. 1 , Fig. 3 , Fig. 4 from Wang et al., 2019
midbrain neuron amount, ameliorated	slc6a3^{zf3173/zf3173}	chemical treatment: clozapine	Fig. 3 from Wang et al., 2019
midbrain neuron morphology, ameliorated	slc6a3^{zf3173/zf3173}	chemical treatment: clozapine	Fig. 3 from Wang et al., 2019
midbrain neuron projection arborization decreased occurrence, abnormal	slc6a3^{zf3173/zf3173}	standard conditions	Fig. 2 , Fig. 3 from Wang et al., 2019
locomotory behavior process quality, abnormal	slc6a3^{zf3173/zf3173}	standard conditions	Fig. 1 , Fig. 3 , Fig. 4 from Wang et al., 2019
brain dopamine decreased amount, abnormal	slc6a3^{zf3173/zf3173}	standard conditions	Fig. 2 from Wang et al., 2019
midbrain neuron morphology, abnormal	slc6a3^{zf3173/zf3173}	standard conditions	Fig. 2 , Fig. 3 from Wang et al., 2019
swimming behavior process quality, ameliorated	slc6a3^{zf3173/zf3173}	chemical treatment: clozapine	Fig. 3 from Wang et al., 2019
midbrain neuron projection arborization occurrence, ameliorated	slc6a3^{zf3173/zf3173}	chemical treatment: clozapine	Fig. 3 from Wang et al., 2019
midbrain neuron decreased amount, abnormal	slc6a3^{zf3173/zf3173}	standard conditions	Fig. 2 , Fig. 3 from Wang et al., 2019
midbrain dopaminergic neuron ab4-th labeling decreased amount, abnormal	slc6a3^{zf3173/zf3173}	standard conditions	Fig. 2 , Fig. 3 from Wang et al., 2019
midbrain dopaminergic neuron ab4-th labeling amount, ameliorated	slc6a3^{zf3173/zf3173}	chemical treatment: clozapine	Fig. 3 from Wang et al., 2019
locomotory behavior process quality, ameliorated	slc6a3^{zf3173/zf3173}	chemical treatment: clozapine	Fig. 3 from Wang et al., 2019
swimming behavior process quality, ameliorated	slc6a3^{zf3173/zf3173}; zf3311Tg	standard conditions	Fig. 4 from Wang et al., 2019
brain epoa expression increased amount, abnormal	slc6a3^{zf3173/zf3173}; zf3311Tg	standard conditions	Fig. 4 from Wang et al., 2019
locomotory behavior process quality, ameliorated	slc6a3^{zf3173/zf3173}; zf3311Tg	standard conditions	Fig. 4 from Wang et al., 2019

Citations